 Dare Bioscience NASDAQ:DAREs stock had its buy rating reaffirmed by analysts at Maxim Group in a report released on Thursday, AnalystRatings.com reports. They currently have a 3.00 target price on the biotechnology companys stock. Maxim Groups price objective suggests a potential upside of 185.71 from the companys previous close. Other equities research analysts have also ... 